Degree of fetal growth restriction associated with schizophrenia risk in a national cohort

M G Eide1, D Moster, L M Irgens

  • 1Norwegian Institute of Public Health, Bergen, Norway. martha.eide@mfr.uib.no

Psychological Medicine
|January 10, 2013
PubMed

Insights

Fetal growth restriction, measured by birth weight and length z scores, is linearly associated with increased schizophrenia risk. Maternal pre-eclampsia also elevates schizophrenia risk, suggesting a role for fetal development in the disorder.

Area of Science:

  • Perinatal epidemiology
  • Psychiatric genetics
  • Developmental neuroscience

Background:

  • Fetal growth restriction is a potential risk factor for schizophrenia.
  • Previous studies have not directly examined the dose-response relationship between fetal growth restriction and schizophrenia risk.
  • Maternal pre-eclampsia, linked to placental dysfunction and poor fetal growth, is also investigated for its association with schizophrenia.

Purpose of the Study:

  • To investigate the linear relationship between the degree of fetal growth restriction and the risk of developing schizophrenia.
  • To determine if maternal pre-eclampsia is associated with an increased risk of schizophrenia.

Main Methods:

  • A population-based cohort study of 873,612 single live births in Norway (1967-1982) was followed to adulthood.
  • Schizophrenia diagnosis (n=2207) was ascertained through the National Insurance Scheme.
  • Fetal growth restriction was quantified using sex-specific z scores for birth weight and birth length for gestational age; maternal pre-eclampsia was recorded based on defined criteria.

Main Results:

  • Schizophrenia risk showed a linear increase with decreasing birth weight for gestational age z scores (p-trend=0.005).
  • The adjusted odds ratio for schizophrenia in the lowest birth weight z-score category (< -3.00) was 2.0 (95% CI 1.2–3.5).
  • Similar trends were observed for birth length z scores, and maternal pre-eclampsia was associated with a 1.3-fold increased risk of schizophrenia (95% CI 1.0–1.8).

Conclusions:

  • The degree of fetal growth restriction and maternal pre-eclampsia are associated with schizophrenia risk.
  • These findings highlight the importance of studying mechanisms influencing fetal growth, including placental function, in the etiology of schizophrenia.
Abstract

Related Concept Videos

Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Schizophrenia01:17

Schizophrenia

Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those diagnosed.
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...